Therapeutic targeting of tumor–stroma interactions

Bibliography

• Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 1989;8:98-101
   PubMed Web of Science ®Google Scholar
• Paunescu V, Bojin FM, Tatu CA, Tumor-associated fibroblasts and mesenchymal stem cells: more similarities than differences. J Cell Mol Med 2010: published online: 24 February 2010, doi: 10.1111/j.1582-4934.2010.01044.x
   Google Scholar
• Darby IA, Hewitson TD. Fibroblast differentiation in wound healing and fibrosis. Int Rev Cytol 2007;257:143-79
   PubMed Web of Science ®Google Scholar
• Ronnov-Jessen L, Petersen OW. Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab Invest 1993;68:696-707
   PubMed Web of Science ®Google Scholar
• Desmouliere A, Guyot C, Gabbiani G. The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol 2004;48:509-17
   PubMed Web of Science ®Google Scholar
• De Wever O, Demetter P, Mareel M, Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 2008;123:2229-38
   PubMedGoogle Scholar
• Tsujino T, Seshimo I, Yamamoto H, Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin Cancer Res 2007;13:2082-90
   PubMedGoogle Scholar
• Tomasek JJ, Gabbiani G, Hinz B, Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002;3:349-63
   PubMed Web of Science ®Google Scholar
• Oh SJ, Kurz H, Christ B, Platelet-derived growth factor-B induces transformation of fibrocytes into spindle-shaped myofibroblasts in vivo. Histochem Cell Biol 1998;109:349-57
   PubMed Web of Science ®Google Scholar
• Webber J, Steadman R, Mason MD, Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res 2010;70:9621-30
   PubMed Web of Science ®Google Scholar
• Micke P, Ostman A. Tumor-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer 2004;45(Suppl 2):S163-75
   PubMedGoogle Scholar
• Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6:392-401
   PubMed Web of Science ®Google Scholar
• Hinz B, Phan SH, Thannickal VJ, The myofibroblast: one function, multiple origins. Am J Pathol 2007;170:1807-16
   PubMed Web of Science ®Google Scholar
• Niu YN, Xia SJ. Stroma-epithelium crosstalk in prostate cancer. Asian J Androl 2009;11:28-35
   PubMed Web of Science ®Google Scholar
• van Zijl F, Mair M, Csiszar A, Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene 2009;28:4022-33
   PubMed Web of Science ®Google Scholar
• Orimo A, Gupta PB, Sgroi DC, Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005;121:335-48
   PubMed Web of Science ®Google Scholar
• Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 2009;28:151-66
   PubMed Web of Science ®Google Scholar
• Lochter A, Galosy S, Muschler J, Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol 1997;139:1861-72
   PubMed Web of Science ®Google Scholar
• Zigrino P, Kuhn I, Bauerle T, Stromal expression of MMP-13 is required for melanoma invasion and metastasis. J Invest Dermatol 2009;129:2686-93
   PubMed Web of Science ®Google Scholar
• Hughes CC. Endothelial-stromal interactions in angiogenesis. Curr Opin Hematol 2008;15:204-9
   PubMed Web of Science ®Google Scholar
• Allinen M, Beroukhim R, Cai L, Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004;6:17-32
   PubMed Web of Science ®Google Scholar
• Infante JR, Matsubayashi H, Sato N, Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 2007;25:319-25
   PubMed Web of Science ®Google Scholar
• De Wever O, Nguyen QD, Van Hoorde L, Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J 2004;18:1016-18
   PubMed Web of Science ®Google Scholar
• Shimoda M, Mellody KT, Orimo A. Carcinoma-associated fibroblasts are a rate-limiting determinant for tumor progression. Semin Cell Dev Biol 2010;21:19-25
   PubMed Web of Science ®Google Scholar
• Ioachim E, Michael M, Stavropoulos NE, A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma. BJU Int 2005;95:655-9
   PubMedGoogle Scholar
• Ioachim E, Charchanti A, Briasoulis E, Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumor invasion and progression. Eur J Cancer 2002;38:2362-70
   PubMed Web of Science ®Google Scholar
• Auvinen P, Tammi R, Parkkinen J, Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 2000;156:529-36
   PubMed Web of Science ®Google Scholar
• Heldin CH, Rubin K, Pietras K, High interstitial fluid pressure – an obstacle in cancer therapy. Nat Rev Cancer 2004;4:806-13
   PubMed Web of Science ®Google Scholar
• Millerot-Serrurot E, Guilbert M, Fourre N, 3D collagen type I matrix inhibits the antimigratory effect of doxorubicin. Cancer Cell Int 2010;10:26
   PubMedGoogle Scholar
• Thomas F, Holly JM, Persad R, Fibronectin confers survival against chemotherapeutic agents but not against radiotherapy in DU145 prostate cancer cells: involvement of the insulin like growth factor-1 receptor. Prostate 2010;70:856-65
   PubMedGoogle Scholar
• Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002;110:673-87
   PubMed Web of Science ®Google Scholar
• Matsunaga T, Takemoto N, Sato T, Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003;9:1158-65
   PubMed Web of Science ®Google Scholar
• Damiano JS, Cress AE, Hazlehurst LA, Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999;93:1658-67
   PubMed Web of Science ®Google Scholar
• Park CC, Zhang HJ, Yao ES, beta1 Integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res 2008;68:4398-405
   PubMedGoogle Scholar
• Cordes N, Seidler J, Durzok R, beta1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury. Oncogene 2006;25:1378-90
   PubMed Web of Science ®Google Scholar
• Maity G, Choudhury PR, Sen T, Culture of human breast cancer cell line (MDA-MB-231) on fibronectin-coated surface induces pro-matrix metalloproteinase-9 expression and activity. Tumour Biol 2011;32:129-38
   PubMedGoogle Scholar
• Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999;43(Suppl):S42-51
   PubMedGoogle Scholar
• Partheen K, Levan K, Osterberg L, External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas. BMC Cancer 2009;9:336
   PubMed Web of Science ®Google Scholar
• Kaur S, Kenny HA, Jagadeeswaran S, beta3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am J Pathol 2009;175(5):2184-96
   PubMedGoogle Scholar
• Sabatino M, Kim-Schulze S, Panelli MC, Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 2009;27:2645-52
   PubMed Web of Science ®Google Scholar
• Abdollahi A, Griggs DW, Zieher H, Inhibition of alphavbeta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 2005;11:6270-9
   PubMed Web of Science ®Google Scholar
• Nam J-M, Onodera Y, Bissell MJ, Breast cancer cells in three-dimensional culture display an enhanced radioresponse after coordinate targeting of integrin alpha5beta1 and fibronectin. Cancer Res 2010;70:5238-48
   PubMedGoogle Scholar
• Spangenberg C, Lausch EU, Trost TM, ERBB2-mediated transcriptional up-regulation of the alpha5beta1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions. Cancer Res 2006;66:3715-25
   PubMedGoogle Scholar
• Desgrosellier JS, Barnes LA, Shields DJ, An integrin alphavbeta3-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med 2009;15:1163-9
   PubMed Web of Science ®Google Scholar
• Schwock J, Dhani N, Cao MP, Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts. Cancer Res 2009;69:4750-9
   PubMed Web of Science ®Google Scholar
• McKenzie JA, Liu T, Goodson AG, Survivin enhances motility of melanoma cells by supporting Akt activation and alpha5 integrin upregulation. Cancer Res 2010;70:7927-37
   PubMed Web of Science ®Google Scholar
• Huang CY, Yu HS, Lai TY, Leptin increases motility and integrin up-regulation in human prostate cancer cells. J Cell Physiol 2010: published online 13 October 2010, doi: 10.1002/jcp.22455
   Google Scholar
• Su Y, Zheng L, Wang Q, The PI3K/Akt pathway upregulates Id1 and integrin alpha4 to enhance recruitment of human ovarian cancer endothelial progenitor cells. BMC Cancer 2010;10:459
   PubMed Web of Science ®Google Scholar
• Yoshioka T, Nishikawa Y, Ito R, Significance of integrin alphavbeta5 and erbB3 in enhanced cell migration and liver metastasis of colon carcinomas stimulated by hepatocyte-derived heregulin. Cancer Sci 2010;101:2011-18
   PubMed Web of Science ®Google Scholar
• Inoki K, Li Y, Zhu T, TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat Cell Biol 2002;4:648-57
   PubMed Web of Science ®Google Scholar
• Yang Z, Lei Z, Li B, Rapamycin inhibits lung metastasis of B16 melanoma cells through down-regulating alphav integrin expression and up-regulating apoptosis signaling. Cancer Sci 2010;101:494-500
   PubMed Web of Science ®Google Scholar
• Lee DY, Li YS, Chang SF, Oscillatory flow-induced proliferation of osteoblast-like cells is mediated by alphavbeta3 and beta1 integrins through synergistic interactions of focal adhesion kinase and Shc with phosphatidylinositol 3-kinase and the Akt/mTOR/p70S6K pathway. J Biol Chem 2010;285:30-42
   PubMed Web of Science ®Google Scholar
• Cabodi S, Di Stefano P, Leal Mdel P, Integrins and signal transduction. Adv Exp Med Biol 2010;674:43-54
   PubMed Web of Science ®Google Scholar
• Parsons JT, Slack-Davis J, Tilghman R, Focal adhesion kinase: targeting adhesion signaling pathways for therapeutic intervention. Clin Cancer Res 2008;14:627-32
   PubMed Web of Science ®Google Scholar
• Kim TH, Kim HI, Soung YH, Integrin (alpha6beta4) signals through Src to increase expression of S100A4, a metastasis-promoting factor: implications for cancer cell invasion. Mol Cancer Res 2009;7:1605-12
   PubMed Web of Science ®Google Scholar
• Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003;22:337-58
   PubMed Web of Science ®Google Scholar
• Schweppe RE, Kerege AA, French JD, Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. J Clin Endocrinol Metab 2009;94:2199-203
   PubMed Web of Science ®Google Scholar
• Hiscox S, Jordan NJ, Morgan L, Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells. Clin Exp Metastasis 2007;24:157-67
   PubMedGoogle Scholar
• Green TP, Fennell M, Whittaker R, Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol 2009;3:248-61
   PubMed Web of Science ®Google Scholar
• Park SI, Zhang J, Phillips KA, Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008;68:3323-33
   PubMed Web of Science ®Google Scholar
• Stupp R, Ruegg C. Integrin inhibitors reaching the clinic. J Clin Oncol 2007;25:1637-8
   PubMed Web of Science ®Google Scholar
• Hariharan S, Gustafson D, Holden S, Assessment of the biological and pharmacological effects of the alphav beta3 and alphav beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol 2007;18:1400-14077
   PubMed Web of Science ®Google Scholar
• Carter A. Integrins as target: first phase III trial launches, but questions remain. J Natl Cancer Inst 2010;102:675-7
   PubMedGoogle Scholar
• Ramakrishnan V, Bhaskar V, Law DA, Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol 2006;5:273-86
   PubMedGoogle Scholar
• Moschos SJ, Sander CA, Wang W, Pharmacodynamic (phase 0) study using etaracizumab in advanced melanoma. J Immunother 2010;33:316-25
   PubMedGoogle Scholar
• Hersey P, Sosman J, O'Day S, A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alphavbeta3, ± dacarbazine in patients with stage IV metastatic melanoma. Cancer 2010;116:1526-34
   PubMed Web of Science ®Google Scholar
• O'Connor PM, Lapointe TK, Beck PL, Mechanisms by which inflammation may increase intestinal cancer risk in inflammatory bowel disease. Inflamm Bowel Dis 2010;16:1411-20
   PubMed Web of Science ®Google Scholar
• Park EJ, Lee JH, Yu GY, Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010;140:197-208
   PubMed Web of Science ®Google Scholar
• Finger EC, Giaccia AJ. Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev 2010;29:285-93
   PubMed Web of Science ®Google Scholar
• Solinas G, Germano G, Mantovani A, Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009;86:1065-73
   PubMed Web of Science ®Google Scholar
• Ly LV, Baghat A, Versluis M, In aged mice, outgrowth of intraocular melanoma depends on proangiogenic M2-type macrophages. J Immunol 2010;185:3481-8
   PubMedGoogle Scholar
• Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 2003;3:276-85
   PubMed Web of Science ®Google Scholar
• Murdoch C, Giannoudis A, Lewis CE. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004;104:2224-34
   PubMed Web of Science ®Google Scholar
• Imtiyaz HZ, Simon MC. Hypoxia-inducible factors as essential regulators of inflammation. Curr Top Microbiol Immunol 2010;345:105-20
   PubMed Web of Science ®Google Scholar
• Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66:605-12
   PubMed Web of Science ®Google Scholar
• Doedens AL, Stockmann C, Rubinstein MP, Macrophage expression of hypoxia-inducible factor-1alpha suppresses T-cell function and promotes tumor progression. Cancer Res 2010;70:7465-75
   PubMed Web of Science ®Google Scholar
• Nowicki A, Szenajch J, Ostrowska G, Impaired tumor growth in colony-stimulating factor 1 (CSF-1)-deficient, macrophage-deficient op/op mouse: evidence for a role of CSF-1-dependent macrophages in formation of tumor stroma. Int J Cancer 1996;65:112-19
   PubMedGoogle Scholar
• Lin EY, Nguyen AV, Russell RG, Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001;193:727-40
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sozzani S, Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors. Semin Cancer Biol 2004;14:155-60
   PubMed Web of Science ®Google Scholar
• Barleon B, Sozzani S, Zhou D, Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996;87:3336-43
   PubMed Web of Science ®Google Scholar
• Mantovani A, Schioppa T, Porta C, Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006;25:315-22
   PubMed Web of Science ®Google Scholar
• Sica A, Rubino L, Mancino A, Targeting tumor-associated macrophages. Expert Opin Ther Targets 2007;11:1219-29
   PubMed Web of Science ®Google Scholar
• Pollard JW. Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol 2008;84:623-30
   PubMed Web of Science ®Google Scholar
• Sica A, Larghi P, Mancino A, Macrophage polarization in tumor progression. Semin Cancer Biol 2008;18:349-55
   PubMed Web of Science ®Google Scholar
• Allavena P, Sica A, Garlanda C, The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev 2008;222:155-61
   PubMed Web of Science ®Google Scholar
• Mantovani A, Schioppa T, Biswas SK, Tumor-associated macrophages and dendritic cells as prototypic type II polarized myeloid populations. Tumori 2003;89:459-68
   PubMedGoogle Scholar
• Lin EY, Li J-F, Gnatovskiy L, Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 2006;66:11238-46
   PubMed Web of Science ®Google Scholar
• Torisu H, Ono M, Kiryu H, Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha. Int J Cancer 2000;85:182-8
   PubMed Web of Science ®Google Scholar
• Orre M, Rogers PA. Macrophages and microvessel density in tumors of the ovary. Gynecol Oncol 1999;73:47-50
   PubMedGoogle Scholar
• Zhang BC, Gao J, Wang J, Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma. Med Oncol 2010: published online 30 July 2010, doi: 10.1007/s12032-010-9638-5
   Google Scholar
• Bingle L, Brown NJ, Lewis CE. The role of tumor-associated macrophages in tumor progression: implications for new anticancer therapies. J Pathol 2002;196:254-65
   PubMed Web of Science ®Google Scholar
• Ojalvo LS, King W, Cox D, High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors. Am J Pathol 2009;174:1048-64
   PubMed Web of Science ®Google Scholar
• Soesatyo M, Biewenga J, van Rooijen N, The in situ immune response of the rat after intraperitoneal depletion of macrophages by liposome-encapsulated dichloromethylene diphosphonate. Res Immunol 1991;142:533-40
   PubMedGoogle Scholar
• Hiraoka K, Zenmyo M, Watari K, Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Sci 2008;99:1595-602
   PubMed Web of Science ®Google Scholar
• Banciu M, Metselaar JM, Schiffelers RM, Antitumor activity of liposomal prednisolone phosphate depends on the presence of functional tumor-associated macrophages in tumor tissue. Neoplasia 2008;10:108-17
   PubMed Web of Science ®Google Scholar
• Allavena P, Signorelli M, Chieppa M, Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 2005;65:2964-71
   PubMed Web of Science ®Google Scholar
• Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5:749-59
   PubMed Web of Science ®Google Scholar
• Hagemann T, Lawrence T, McNeish I, “Re-educating” tumor-associated macrophages by targeting NF-kappaB. J Exp Med 2008;205:1261-8
   PubMed Web of Science ®Google Scholar
• Sethi T, Rintoul RC, Moore SM, Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999;5:662-8
   PubMed Web of Science ®Google Scholar
• Fridman R, Giaccone G, Kanemoto T, Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc Natl Acad Sci USA 1990;87:6698-702
   PubMed Web of Science ®Google Scholar
• Berube M, Talbot M, Collin C, Role of the extracellular matrix proteins in the resistance of SP6.5 uveal melanoma cells toward cisplatin. Int J Oncol 2005;26:405-13
   PubMedGoogle Scholar
• Johnson JI, Decker S, Zaharevitz D, Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001;84:1424-31
   PubMed Web of Science ®Google Scholar
• Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003;9:4227-39
   PubMed Web of Science ®Google Scholar
• Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-15
   PubMed Web of Science ®Google Scholar
• Rossi F, Yozgat Y, de Stanchina E, Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib. Mol Cancer Res 2010;8:1271-83
   PubMed Web of Science ®Google Scholar
• Hiscox S, Barnfather P, Hayes E, Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells. Breast Cancer Res Treat 2011;125:659-69
   PubMedGoogle Scholar
• Hehlgans S, Lange I, Eke I, 3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226. Radiother Oncol 2009;92:371-8
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Neyns B, Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010;28:2712-18
   PubMed Web of Science ®Google Scholar
• Nam JM, Chung Y, Hsu HC, beta1 integrin targeting to enhance radiation therapy. Int J Radiat Biol 2009;85:923-8
   PubMed Web of Science ®Google Scholar
• Kim TJ, Landen CN, Lin YG, Combined anti-angiogenic therapy against VEGF and integrin alphavbeta3 in an orthotopic model of ovarian cancer. Cancer Biol Ther 2009;8:2263-72
   PubMed Web of Science ®Google Scholar
• Alva A, Slovin S, Daignault S, Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Invest New Drugs 2010: published online 4 November 2010, doi: 10.1007/s10637-010-9573-5
   Google Scholar
• Bradley DA, Daignault S, Ryan CJ, Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Invest New Drugs 2010: published online 25 March 2010, doi: 10.1007/s10637-010-9420-8
   Google Scholar
• McNeel DG, Eickhoff J, Lee FT, Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin Cancer Res 2005;11:7851-60
   PubMed Web of Science ®Google Scholar
• Delbaldo C, Raymond E, Vera K, Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors. Invest New Drugs 2008;26:35-43
   PubMed Web of Science ®Google Scholar
• Ricart AD, Tolcher AW, Liu G, Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a Phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res 2008;14:7924-9
   PubMed Web of Science ®Google Scholar
• Ng CM, Bai S, Takimoto CH, Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-alpha5beta1 integrin monoclonal antibody (volociximab) in cancer patients. Cancer Chemother Pharmacol 2009;65:207-17
   Google Scholar